ArticleFrontiers in oncology2025
Global burden and future trends of gastric cancer in women of reproductive age: estimates from the GBD 2021 Study, 1990-2050.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges.Translational gastroenterology and hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related mortality worldwide. Although incidence is higher in men, GC remains a significant health issue for women of reproductive age (15-49 years) due to biological, hormonal, and socioeconomic factors. However, this population has been underrepresented in cancer surveillance. This study assessed global, regional, and national GC burden among women from 1990 to 2021 and projected future trends to 2050 using Global Burden of Disease (GBD) 2021 data. Methods: We analyzed GBD 2021 data from 204 countries and territories for females aged 15-49. Indicators included incidence, mortality, disability-adjusted life years (DALYs), and age-standardized rates (ASRs). Temporal trends were quantified using estimated annual percentage change (EAPC) and Joinpoint regression, stratified by Socio-demographic Index (SDI). Forecasts to 2050 were derived from age-period-cohort modeling. This study follows GATHER guidelines. Results: From 1990 to 2021, the GC burden in women aged 15-49 declined globally: ASPR decreased from 10.42 to 5.41 per 100,000 (EAPC -2.11), ASIR from 4.61 to 2.13 (EAPC -2.56), ASMR from 2.02 to 0.89 (EAPC -3.02), and ASDR from 59.6 to 23.8 per 100,000 (EAPC -3.00). High-SDI regions achieved the steepest reductions, while low-SDI regions showed modest progress. The burden peaked in women aged 45-49. By 2050, ASIR is projected to reach 2.81 per 100,000 persons (95% CI: 2.06, 3.56), reflecting an increase relative to 2021, largely in low- and middle-SDI countries. Conclusions: Despite overall global declines, substantial regional and socioeconomic disparities persist. High-SDI regions benefit from improved healthcare and screening, whereas low-SDI regions face slower progress. Strengthening H. pylori screening, early detection, dietary interventions, and healthcare equity is essential. Region-specific strategies are needed to further reduce the GC burden among women of reproductive age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.